agentsclimarketplace

Jama study design

Skill brycewang-stanford/Awesome-Journal-Skills/JAMA-Skills/skills/jama-study-design

Journal-specific Claude Code/Codex skill packs covering mainstream journals — AER, QJE, Nature, Cell, 管理世界, 经济研究 & 200+ more — your fast track to getting published. | 覆盖主流期刊的 Claude Code/Codex 期刊技能包,从选题、识别策略到表格规范与审稿回复全流程,助你快速发论文。

Install
npx -y skills add brycewang-stanford/Awesome-Journal-Skills --skill jama-study-design

Assembled from the repository path, not quoted from the project. Check it against their README if it does not work.

What its author says it does

Copied from the file, not written here

Use when locking the study design and internal-validity safeguards for a JAMA clinical manuscript (RCT, cohort, diagnostic, or systematic review). Strengthens design choices; it does NOT pick the reporting checklist or run the statistics.

SKILL.md

6.8 KB, as published. Nobody here has run it

Study Design & Internal Validity (jama-study-design)

When to trigger

  • Choosing or defending the design: RCT vs cohort vs case-control vs diagnostic
  • A reviewer will ask whether the analysis is intention-to-treat or per-protocol
  • Bias, confounding, or missing data threaten the primary inference
  • The design and the reporting checklist need to be aligned before writing

Design-specific safeguards JAMA reviewers expect

Randomized clinical trials

  • A single, pre-specified primary outcome; secondary outcomes clearly labeled
  • Adequate randomization (sequence generation) and allocation concealment
  • Blinding of participants, clinicians, outcome assessors where feasible — state what was blinded
  • Intention-to-treat as the primary analysis; per-protocol only as secondary/sensitivity
  • A priori sample-size / power calculation tied to the primary outcome
  • Pre-defined stopping rules and handling of interim analyses

Cohort / case-control (observational)

  • Explicit confounding control: prespecified covariates, adjustment strategy, DAG reasoning
  • Clear definitions of exposure, outcome, and follow-up windows; avoid immortal-time bias
  • Selection-bias and information-bias appraisal; how participants entered the sample
  • Association, not causation — design and language must respect this

Diagnostic-accuracy studies

  • Pre-specified reference standard, applied to all participants, blinded to index test
  • Consecutive or random enrollment; report spectrum of disease
  • Pre-defined thresholds; report sensitivity/specificity/predictive values with CIs

Systematic reviews / meta-analyses

  • Pre-registered protocol (e.g., PROSPERO), pre-specified eligibility and outcomes
  • Comprehensive, reproducible search; duplicate screening and extraction
  • Risk-of-bias assessment; pre-planned heterogeneity and sensitivity analyses

Decision table

QuestionDesign / action
Does an intervention cause an outcome?RCT; if infeasible, strong quasi-design
What is the prognosis / risk of an exposure?Prospective cohort with confounder plan
How accurate is a test?Diagnostic-accuracy study (vs reference)
What does the totality of evidence show?Systematic review ± meta-analysis
Rare outcome, exposure already occurredCase-control (watch selection bias)

Checklist

  • Primary outcome is single, pre-specified, patient-relevant
  • For RCTs: randomization, allocation concealment, blinding stated; ITT is primary
  • Sample-size / power calculation present and tied to the primary outcome
  • Confounding/bias strategy explicit and pre-specified (observational)
  • Reference standard and blinding defined (diagnostic)
  • Protocol pre-registered (RCT and systematic review)
  • Missing-data handling pre-specified (not improvised post hoc)
  • Design choice matches the EQUATOR checklist you will use

Anti-patterns

  • Promoting a secondary or post hoc outcome to "primary" after seeing results
  • Per-protocol analysis presented as primary for an RCT
  • "Adjusted for everything" with no pre-specified covariate rationale
  • Causal claims from an observational design
  • Reference standard chosen or applied after knowing the index-test result
  • No power calculation, then attributing a null result to "trends"

Worked example: locking the design (illustrative)

Vignette (illustrative): a multicenter randomized clinical trial, N = 3,400 adults with acute kidney injury across 18 sites, early vs standard renal-replacement timing; pre-specified primary outcome 28-day all-cause mortality, 28.5% vs 31.2%, absolute risk difference -2.7 percentage points (95% CI, -6.1 to 0.7). For a Journal of the American Medical Association Original Investigation, the design safeguards a JAMA reviewer checks: a single pre-specified primary outcome, documented allocation concealment, intention-to-treat as primary (per-protocol only as sensitivity), and an a priori power calculation tied to mortality. The 95% CI crossing zero means the trial does not establish benefit — the Conclusions must say "no significant difference," not "a trend toward benefit."

Reviewer pushback and the JAMA fix

  • "Is this intention-to-treat or per-protocol?" Fix: make ITT the primary analysis and relegate per-protocol to clearly labeled sensitivity.
  • "Primary outcome looks chosen after seeing the data." Fix: cite the registry/protocol; demote any post hoc outcome to exploratory.
  • "Causal language from an observational design." Fix: switch to associational verbs and frame confounding as a residual threat.

Calibration anchors (hedge where uncertain): a single pre-specified primary outcome, allocation concealment, ITT-as-primary, and an a priori power calculation are durable JAMA expectations; the matching EQUATOR checklist (CONSORT/STROBE/STARD/PRISMA) follows from the design — confirm specifics against current author guidelines.

Operating pass for JAMA

Run this as a concrete capability pass. First lock the clinical question, patient population, estimand or endpoint, safety/ethics issue, and reporting checklist; then test whether the manuscript addresses clinical reviewers who ask whether the evidence changes patient care, policy, or medical decision-making while satisfying reporting standards.

  • Primary move: Return a claim-evidence-risk ledger; every recommendation must point to a manuscript location or missing artifact.
  • Decision ledger: return claim / evidence / blocker / next edit rows so the next pass can patch the manuscript directly.
  • Sibling comparison: compare against NEJM for field-changing clinical medicine, Lancet for global-health breadth, specialty journals for narrower clinical domains; if the neighboring outlet has the stronger audience claim, recommend re-routing before polishing.
  • Verification floor: before submission-ready advice, re-open resources/official-source-map.md for volatile rules and name the one unresolved fact that could change the recommendation.

Output format

【Design】RCT / cohort / case-control / diagnostic / systematic review
【Primary outcome】... (pre-specified: yes/no)
【Key validity safeguards in place】...
【Validity gaps to fix】...
【Causal vs associational claim】...
【Matching EQUATOR checklist】CONSORT / STROBE / STARD / PRISMA
【Next skill】jama-reporting-standards

Keep looking

Skills are one crate of 328,083. Ordering is by how many stacks a row turns up in, so the top of any crate is what has actually been picked rather than what has the most stars.